A new standard for mastocytosis

Affiliations

Comment

David Killock. Nat Rev Clin Oncol. 2022 Feb.

. 2022 Feb;19(2):71.

doi: 10.1038/s41571-021-00592-z.

No abstract available

Comment on

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, Vannucchi AM, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh ST, Sen J, Lin HM, Mar BG, DeAngelo DJ. Gotlib J, et al. Nat Med. 2021 Dec;27(12):2192-2199. doi: 10.1038/s41591-021-01539-8. Epub 2021 Dec 6. Nat Med. 2021. PMID: 34873345 Free PMC article.
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. DeAngelo DJ, et al. Nat Med. 2021 Dec;27(12):2183-2191. doi: 10.1038/s41591-021-01538-9. Epub 2021 Dec 6. Nat Med. 2021. PMID: 34873347 Free PMC article. Clinical Trial.

1. DeAngelo, D. J. et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat. Med. https://doi.org/10.1038/s41591-021-01538-9 (2021) - DOI - PubMed - PMC
1. Gotlib, J. et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat. Med. https://doi.org/10.1038/s41591-021-01539-8 (2021) - DOI - PubMed - PMC